IntegraGen is pleased to announce that a full summary of the results of validation studies for its proprietary miR-31-3p expression assay has been published online in Biomarker Insights following peer review.

The article entitled "Technical validation of a reverse-transcription quantitative polymerase chain reaction in vitro diagnostic test for the determination of miR-31-3p expression levels in formalin-fixed paraffin-embedded (FFPE) metastatic colorectal cancer tumor specimens" examines the test's analytical sensitivity, specificity, robustness, reproducibility, repeatability and accuracy under a number of conditions and on different platforms.

Data from these studies confirm the assay's ability to provide an analytically accurate assay for the clinical measurement of miR-31-3p from FFPE tumor samples in patients with metastatic colorectal cancer.